General Mills Q4 earnings preview: Volume recovery, GLP-1 fears in focus

Key Facts

1General Mills is set to report Q4 earnings, with investors focused on volume recovery and the impact of GLP-1 weight-loss drugs.

In a move that highlights ongoing challenges in the consumer staples sector, markets are awaiting General Mills' Q4 earnings release. According to reports, investor focus is on the extent of volume recovery after periods of decline, as well as the growing impact of GLP-1 weight-loss drugs on consumption patterns.

General Mills faces dual pressure from shrinking demand for traditional products and shifting dietary preferences toward healthier alternatives, with analysts expecting relatively flat revenue. Analysts note that GLP-1 drugs may reduce snacking and cereal consumption, adding uncertainty to the sector's outlook.

GIS shares closed at $36.38 on June 29, 2026, within a daily range of $35.94–$36.54. The market is eyeing the upcoming Q4 results as a key catalyst, with potential share movement if figures beat cautious expectations.